• Business Wire

    Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSX:VRX) and Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that they have entered into an amendment to their Agreement and Plan of Merger, dated February 20, 2015. Pursuant to the amendment, Valeant increased the offer price to acquire all the outstanding common stock of Salix from $158.00 per share to $173.00

  • David Becker

    Highflying bio-tech stocks returned to the forefront this week, after experiencing a substantial decline during most of March and the first half of April. Gilead Sciences (NASDAQ:GILD) tumbled nearly 24% from its high in late February before bouncing last week ahead of its earnings. The stock is now in the process of returning to leadership,